These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

50 related articles for article (PubMed ID: 38794126)

  • 1. Selexipag, a selective prostacyclin receptor agonist in pulmonary arterial hypertension: a pharmacology review.
    Honorato Pérez J
    Expert Rev Clin Pharmacol; 2017 Jul; 10(7):753-762. PubMed ID: 28524738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switching from Beraprost to Selexipag in the Treatment of Pulmonary Arterial Hypertension: Insights from a Phase IV Study of the Japanese Registry (The EXCEL Study: EXChange from bEraprost to seLexipag Study).
    Tamura Y; Kumamaru H; Tsujino I; Suda R; Abe K; Inami T; Horimoto K; Adachi S; Yasuda S; Sera F; Taniguchi Y; Kuwana M; Tatsumi K;
    Pharmaceuticals (Basel); 2024 Apr; 17(5):. PubMed ID: 38794126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study.
    Frost A; Janmohamed M; Fritz JS; McConnell JW; Poch D; Fortin TA; Miller CE; Chin KM; Fisher M; Eggert M; McEvoy C; Benza RL; Farber HW; Kim NH; Pfister T; Shiraga Y; McLaughlin V
    J Heart Lung Transplant; 2019 Jan; 38(1):43-50. PubMed ID: 30391194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostacyclin for pulmonary arterial hypertension.
    Barnes H; Yeoh HL; Fothergill T; Burns A; Humbert M; Williams T
    Cochrane Database Syst Rev; 2019 May; 5(5):CD012785. PubMed ID: 31042010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initial Triple Combination Therapy Including Intravenous Prostaglandin I
    Tamura Y; Kumamaru H; Nishimura S; Nakajima Y; Matsubara H; Taniguchi Y; Tsujino I; Shigeta A; Kinugawa K; Kimura K; Tatsumi K
    Int Heart J; 2023; 64(4):684-692. PubMed ID: 37518350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in the Characteristics and Initial Treatments of Pulmonary Hypertension Between 2008 and 2020 in Japan.
    Tamura Y; Kumamaru H; Inami T; Matsubara H; Hirata KI; Tsujino I; Suda R; Miyata H; Nishimura S; Sigel B; Takano M; Tatsumi K;
    JACC Asia; 2022 Jun; 2(3):273-284. PubMed ID: 36338395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical efficacy and safety of selexipag in children and young adults with idiopathic and heritable pulmonary arterial hypertension.
    Takatsuki S; Nakayama T; Shimizu Y; Kawai R; Matsuura H
    Cardiol Young; 2023 Feb; 33(2):196-200. PubMed ID: 35383553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvements in French risk stratification score were correlated with reductions in mean pulmonary artery pressure in pulmonary arterial hypertension: a subanalysis of the Japan Pulmonary Hypertension Registry (JAPHR).
    Tamura Y; Kumamaru H; Abe K; Satoh T; Miyata H; Ogawa A; Tanabe N; Hatano M; Yao A; Tsujino I; Fukuda K; Kimura H; Kuwana M; Matsubara H; Tatsumi K;
    BMC Pulm Med; 2021 Jan; 21(1):28. PubMed ID: 33446139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk stratification and medical therapy of pulmonary arterial hypertension.
    Galiè N; Channick RN; Frantz RP; Grünig E; Jing ZC; Moiseeva O; Preston IR; Pulido T; Safdar Z; Tamura Y; McLaughlin VV
    Eur Respir J; 2019 Jan; 53(1):. PubMed ID: 30545971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives.
    Humbert M; Guignabert C; Bonnet S; Dorfmüller P; Klinger JR; Nicolls MR; Olschewski AJ; Pullamsetti SS; Schermuly RT; Stenmark KR; Rabinovitch M
    Eur Respir J; 2019 Jan; 53(1):. PubMed ID: 30545970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of an Orally Administered Selective Prostacyclin Receptor Agonist, Selexipag, in Japanese Patients With Pulmonary Arterial Hypertension.
    Tanabe N; Ikeda S; Tahara N; Fukuda K; Hatano M; Ito H; Nakayama T; Anzai T; Hashimoto A; Inoue T; Kajinami K; Kihara Y; Kinoshita H; Kuwahara K; Murohara T; Okazaki O; Sakai S; Satoh T; Takeda Y; Takeishi Y; Taniguchi M; Watanabe H; Yamamoto T; Yamauchi-Takihara K; Yoshioka K; Sasayama S
    Circ J; 2017 Aug; 81(9):1360-1367. PubMed ID: 28420826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selexipag for the Treatment of Pulmonary Arterial Hypertension.
    Sitbon O; Channick R; Chin KM; Frey A; Gaine S; Galiè N; Ghofrani HA; Hoeper MM; Lang IM; Preiss R; Rubin LJ; Di Scala L; Tapson V; Adzerikho I; Liu J; Moiseeva O; Zeng X; Simonneau G; McLaughlin VV;
    N Engl J Med; 2015 Dec; 373(26):2522-33. PubMed ID: 26699168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The molecular targets of approved treatments for pulmonary arterial hypertension.
    Humbert M; Ghofrani HA
    Thorax; 2016 Jan; 71(1):73-83. PubMed ID: 26219978
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.